Supernus Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - SUPN
Portfolio Pulse from
Levi & Korsinsky has initiated an investigation into Supernus Pharmaceuticals, Inc. for potential securities fraud following the failure of its Phase 2b study of SPN-820 for treatment-resistant depression to meet its primary endpoint.
February 21, 2025 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Supernus Pharmaceuticals faces a legal investigation by Levi & Korsinsky for potential securities fraud after its SPN-820 study failed to meet primary endpoints.
The failure of the SPN-820 study is a significant setback for Supernus Pharmaceuticals, potentially affecting investor confidence and leading to legal challenges. The investigation by Levi & Korsinsky could result in negative sentiment and pressure on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100